Neurodevelopmental epilepsies (NDEs) — including Dravet syndrome (SCN1A), KCNQ2 encephalopathy, CDKL5 deficiency disorder, Angelman syndrome (UBE3A), and others — represent a compelling frontier for gene therapy. These are monogenic disorders with well-defined genetic targets, early onset (enabling intervention before irreversible damage), and profound unmet need (>30% of patients are drug-resistant).
This page maps the competitive landscape of AAV-based approaches and evaluates alternative delivery technologies that could deliver genetic payloads more effectively, safely, or broadly.
| Company | Target | Indication | Vector/Approach | Phase | Route | Status |
|---|---|---|---|---|---|---|
| Stoke Therapeutics | SCN1A | Dravet syndrome | ASO (STK-001) | Phase 2 (BEACON) | Intrathecal | Recruiting — Phase 2 data Q2-Q3 2026 |
| Encoded Therapeutics | SCN1A | Dravet syndrome | AAV9-ETX101 (gene activation) | Phase 1 (LAYLA) | ICM | First patient dosed Q1 2026 |
| GeneTx/Ultragenyx | UBE3A | Angelman syndrome | ASO (GTX-102) | Phase 2 | IV | BLA submission expected Q3-Q4 2026 |
| Roche/Neurocrine | SCN1A | Dravet syndrome | AAV-SCN1A | Preclinical | — | IND-enabling |
| Vigonvita | CDKL5 | CDKL5 deficiency | AAV | Preclinical | — | IND-enabling, IND filing 2026 |
| Various academic | KCNQ2 | KCNQ2 encephalopathy | AAV-KCNQ2 | Preclinical | — | Research |
| Takeda/SB | SLC6A1 | SLC6A1-related epilepsy | AAV | Discovery | — | Preclinical |
| Various academic | STXBP1 | STXBP1 encephalopathy | AAV | Preclinical | — | Research |
| Various academic | GABRB3 | GABRB3-related epilepsy | AAV | Preclinical | — | Research |
| Various academic | PCDH19 | PCDH19-related epilepsy | AAV | Preclinical | — | Research |
| Company | Drug | Target | Indication | Phase | Notes |
|---|---|---|---|---|---|
| Stoke Therapeutics | STK-001 | SCN1A | Dravet syndrome | Phase 2 (BEACON, NCT05482706) | FDA BTD granted; Phase 2 data Q2-Q3 2026 |
| Stoke Therapeutics | STK-002 | SCN1A | Dravet (adult) | Phase 1 | Higher dose cohort, 18+ years |
| GeneTx/Ultragenyx | GTX-102 | UBE3A | Angelman syndrome | Phase 2 (KIK-AS-02) | BLA submission expected Q3-Q4 2026 |
| Roche | — | SCN1A | Dravet | Preclinical | Partnered with Neurocrine |
| Entity | Focus | Status |
|---|---|---|
| Stoke Therapeutics (NASDAQ: STOK) | SCN1A ASO (STK-001/002) | Phase 2, FDA BTD, BLA prep |
| Encoded Therapeutics (private) | SCN1A AAV gene activation | Phase 1 (LAYLA), Series D funded |
| Ultragenyx (NASDAQ: UGX) | UBE3A ASO (GTX-102) | Phase 2, BLA submission expected 2026 |
| Roche/Neurocrine (NASDAQ: NBIX) | SCN1A AAV | IND-enabling |
| Vigonvita Sciences (private, China) | CDKL5 AAV | IND-enabling, IND filing 2026 |
| GeneTx Biotherapeutics (Ultragenyx subsidiary) | UBE3A ASO (GTX-102) | Phase 2, BLA prep |
| UC Berkeley (Bhatt group) | SCN1A gene therapy | Preclinical |
| Boston Children's (Berry-Kravis) | Multiple NDE | Clinical |
| Platform | Mechanism | Advantages | Limitations | Key Players |
|---|---|---|---|---|
| Lipid nanoparticles (LNPs) | Encapsulate mRNA/DNA in ionizable lipid | Redosable, no immunogenicity, large cargo | Transient expression, liver tropism | Moderna, BioNTech, Arcturus |
| Exosomes/EVs | Cell-derived vesicles with targeting ligands | Natural BBB crossing, low immunogenicity | Manufacturing scale, cargo loading efficiency | Codiak, Evox, Anjarium |
| Polymer nanoparticles | PLGA/PEI encapsulation | Tunable release, large cargo | BBB penetration, cell specificity | Stoke Therapeutics, academic |
| Cell-penetrating peptides | Peptide-mediated delivery | Small, non-immunogenic | Limited cargo size, endosomal escape | — |
| Vector | Cargo Capacity | Advantages | Limitations | Programs |
|---|---|---|---|---|
| Lentivirus (LV) | ~8kb | Large cargo, integrating | Insertional mutagenesis risk | Bluebird Bio (other indications) |
| HSV-1 amplicons | ~150kb | Massive cargo, neurotropic | Cytotoxicity, manufacturing | Academic |
| Engineered AAV (PHP.eB, AAV.CAP-B10) | ~4.7kb | Enhanced BBB crossing | Species-specific (mouse vs human divergence) | Broad, Voyager |
| Anc80L65 | ~4.7kb | Ancestral AAV, broad tropism | Early development | academic |
| Technology | Mechanism | Potential for NDE | Maturity |
|---|---|---|---|
| Base editing (in vivo) | Correct point mutations without DSBs | SCN1A missense variants (~40% of Dravet) | Preclinical |
| Prime editing | Insert/delete/replace without DSBs | Broader variant coverage than base editing | Early preclinical |
| RNA editing (ADAR) | Endogenous enzyme redirected via guide RNA | Transient, reversible, redosable | Phase 1 (other indications) |
| ASOs (intrathecal) | Splice modulation or knockdown | STXBP1 upregulation, SCN1A splice correction | Phase 2 (Stoke Therapeutics STK-001 for Dravet) |
| CRISPRa/dCas9 | Transcriptional activation | Upregulate haploinsufficient genes (SCN1A, CDKL5) | Preclinical |
| Focused ultrasound + microbubbles | Transient BBB opening for IV vectors | Enable systemic delivery of any payload | Phase 1-2 |
| Convection-enhanced delivery (CED) | Pressure-driven interstitial infusion | Bypass BBB, large-volume distribution | Phase 1-2 (other indications) |
Lipid nanoparticles (LNPs) have revolutionized mRNA delivery for COVID-19 vaccines and represent a promising alternative to AAV vectors for CNS gene therapy. Unlike AAV, LNPs are non-viral, redosable, and lack viral genome integration risks.
| Approach | Mechanism | Status | Key Players |
|---|---|---|---|
| Surface ligand decoration | Angiopep-2, transferrin for BBB crossing | Preclinical | Various academic |
| Ionizable lipid optimization | Enhanced CNS tropism via lipid design | Preclinical | Moderna, BioNTech |
| Focused ultrasound | Temporary BBB opening with microbubbles | Phase 1 | CarThera, ClinicalTrials.gov |
| Intraparenchymal injection | Direct brain delivery bypasses BBB | Preclinical | Various academic |
| Intranasal delivery | Olfactory pathway to CNS | Preclinical | Various academic |
| Program | Target | Approach | Status |
|---|---|---|---|
| Moderna's CNS LNP platform | Multiple | mRNA delivery for protein replacement | Preclinical |
| BioNTech's CNS programs | Various | LNP-mRNA for CNS disorders | Discovery |
| Academic collaborations | SCN1A | LNP-mRNA for Dravet | Research |
Exosomes (30-150nm extracellular vesicles) represent a naturally occurring delivery system that can cross the BBB and deliver cargo to neurons. Unlike synthetic nanoparticles, exosomes are cell-derived and carry endogenous proteins that may enhance CNS targeting.
| Company | Focus | Status | Approach |
|---|---|---|---|
| Codiak BioSciences | Exosome therapeutics | Clinical (oncology) | EngEx platform |
| Evox Therapeutics | Rare disease | Preclinical | Deliver siRNA/mRNA |
| Anjarium Biosciences | CNS | Preclinical | Hybrid exosome-LNP |
| Capricor Therapeutics | Exosomes for various | Clinical | Cardiac, potential CNS |
| AgeX Therapeutics | Cell-derived EVs | Research | Various |
Base editing (CRISPR-based precision editing without double-strand breaks) and prime editing (insertions, deletions, all 12 types of point mutations) represent next-generation gene therapy approaches that could address the underlying genetic cause of NDE.
Target: ~40% of Dravet patients have missense variants that could be corrected
Approach: In vivo base editing to correct pathogenic variants
| Company/Group | Status | Approach | Notes |
|---|---|---|---|
| Beam Therapeutics | Preclinical | Base editing platform | Multiple CNS programs |
| Prime Medicine | Preclinical | Prime editing | Broader capability |
| Verve Therapeutics | Clinical (cardiovascular) | In vivo base editing | First human data |
| Academic (UC Berkeley) | Research | AAV-base editor for Dravet | Proof-of-concept |
Challenge: Delivering editing machinery (Cas9, guide RNA, template) to neurons
| Challenge | Solution Approaches |
|---|---|
| Large cargo (Cas9 + gRNA + template) | Split-intein systems, smaller Cas9 variants (SaCas9, CasMINI) |
| BBB delivery | ICV, ICM, or focused ultrasound |
| Editing efficiency | Optimize promoter, regulatory elements |
| Immune response | Self-delivering RNP, lipid encapsulation |
| Indication | Target | Approach | Estimated Timeline |
|---|---|---|---|
| Dravet (missense) | SCN1A | Base editing | 2027-2028 IND |
| Angelman | UBE3A | Prime editing | 2028-2029 |
| KCNQ2 | KCNQ2 | Base editing | Research |
| STXBP1 | STXBP1 | Base editing | Research |
| Company | Platform | Pipeline | Status |
|---|---|---|---|
| Beam Therapeutics | Base editing | Multiple CNS | Preclinical |
| Prime Medicine | Prime editing | Multiple | Preclinical |
| Verve Therapeutics | Base editing | CV first | Phase 1 |
| CRISPR Therapeutics | CRISPR-Cas9 | Multiple | Various |
| Intellia Therapeutics | LNP CRISPR | Multiple | Clinical |
RNA editing represents a paradigm shift in gene therapy — rather than permanently altering the genome, it modifies RNA transcripts to restore protein function. This approach offers unique advantages for neurodevelopmental epilepsies: transient but repeatable dosing, reduced off-target concerns, and the ability to correct disease-causing mutations without irreversible genomic changes.
1. ADAR-Mediated Editing (A→I)
2. RESTORE Platform
3. CRISPR-Derived RNA Editing
| Advantage | Description |
|---|---|
| Redosability | Can repeat dosing without immune concerns |
| Transient effect | Allows titration of expression levels |
| Safety | No genomic integration, reversible |
| Variant flexibility | Can address many mutation types with same platform |
| Timing control | Expression can be modulated by dosing schedule |
| No packaging limits | Can deliver full-length transcripts |
| Challenge | Current Approaches |
|---|---|
| Duration | Expression typically 1-2 weeks; may require repeat dosing |
| Delivery | Brain delivery remains difficult; similar BBB challenges to other modalities |
| Efficiency | Editing efficiency varies by tissue and cell type |
| Specificity | Off-target editing in non-target tissues possible |
| Validation | Less clinical validation than ASOs or AAV |
SCN1A (Dravet Syndrome)
KCNQ2 Encephalopathy
Angelman Syndrome (UBE3A)
| Company | Platform | Focus | Status |
|---|---|---|---|
| ProMis Neuroscience | ADAR | SCN1A, others | Preclinical |
| Shape Therapeutics | RNA editing | CNS | Preclinical |
| Rewind Therapeutics | ADAR | Neurological | Preclinical |
| Korro Bio | ADAR | CNS, hepatic | Preclinical |
| Hapa Therapeutics | RNA editing | Various | Research |
| Ascidian Therapeutics | RNA editing | Multiple | Preclinical |
| Feature | ASO | AAV Gene Therapy | Base Editing | RNA Editing |
|---|---|---|---|---|
| Duration | Weeks-months | Years | Permanent | Days-weeks |
| Redosability | Yes | Limited | Limited | Yes |
| Clinical validation | High (Spinal Muscular Atrophy) | Moderate (multiple programs) | Early | Minimal |
| Delivery | Intrathecal | ICV/ICM | ICV/ICM | Various |
| Gene size limits | None | ~4.7kb | ~4.7kb | None |
| Off-target risk | Splice off-target | Insertional | Genomic off-target | RNA off-target |
Focused ultrasound (FUS) combined with microbubbles represents a transformative approach to enabling non-invasive delivery of gene therapy vectors across the blood-brain barrier (BBB). This technology uses focused acoustic energy to temporarily open the BBB, allowing systemically administered therapeutics to reach the brain parenchyma.
| Advantage | Description |
|---|---|
| Non-invasive | Avoids surgical injection (ICV/ICM), reduces surgical risks |
| Repeatable | Can perform multiple treatment sessions if needed |
| Targeted | Can focus on specific brain regions (e.g., hippocampus, cortex) |
| Scalable | Can treat multiple brain regions in one session |
| Platform | Works with any IV-delivered therapeutic (AAV, LNP, ASO, small molecules) |
| Parameter | Typical Range | Notes |
|---|---|---|
| Ultrasound frequency | 0.2-1 MHz | Lower frequency = deeper penetration |
| Pressure threshold | 0.3-0.6 MPa | Must exceed threshold for BBB opening |
| Pulse duration | 10-30 ms | Longer pulses increase opening magnitude |
| Treatment duration | 1-2 minutes per target | Multiple sonications possible |
| Opening duration | 4-6 hours | Time window for therapeutic delivery |
| Company/Institution | Indication | Status | Approach |
|---|---|---|---|
| CarThera | Glioblastoma | Phase 1 | SonoCloud implantable device |
| Insightec | Tremor (Parkinson's) | Approved | Exablate Neuro device |
| Various academic | Alzheimer's | Phase 1 | Blood-brain barrier opening |
| Various academic | ALS | Phase 1 | FUS for drug delivery |
| Various academic | NDE | Preclinical | AAV delivery with FUS |
Dravet Syndrome (SCN1A)
Angelman Syndrome (UBE3A)
KCNQ2, CDKL5, STXBP1
| Gene Therapy | FUS Application | Status | Notes |
|---|---|---|---|
| AAV9-IV | FUS to cortex | Preclinical | Enhanced neuronal transduction |
| LNP-mRNA | FUS for BBB opening | Preclinical | Increased brain expression |
| ASO | FUS enhancement | Research | Improved CNS distribution |
| Base editor | FUS delivery | Early research | Proof-of-concept in mice |
Convection-enhanced delivery (CED) is a surgical technique that uses pressure-driven bulk flow to infuse therapeutics directly into brain tissue, bypassing the blood-brain barrier entirely. Unlike simple injection, CED uses continuous positive pressure to create a pressure gradient that drives fluid flow through the interstitial space, enabling distribution over volumes far larger than possible with diffusion alone.
| Advantage | Description |
|---|---|
| BBB bypass | Direct delivery to brain, no need for BBB-crossing vectors |
| Large distribution | Can cover whole brain regions (hemispheres, cerebellum) |
| No systemic exposure | Minimal off-target effects, lower immunogenicity |
| Dose control | Adjustable infusion rates, can target specific regions |
| Gene-size independent | Can deliver any size payload (AAV, LV, HSV-1) |
| Parameter | Typical Range | Notes |
|---|---|---|
| Infusion rate | 0.5-10 μL/min | Higher rates = larger distribution |
| Catheter design | Single or multiple | Smart catheters with reflux prevention |
| Distribution volume | 1-10 cm per infusion | Depends on rate, duration, tissue properties |
| Reflux prevention | Critical | Requires proper catheter design and technique |
| Real-time imaging | MRI with gadolinium | Co-infused contrast tracks distribution |
| Indication | Therapeutic | Status | Notes |
|---|---|---|---|
| Parkinson's | GDNF, AAV-AADC | Phase 1-2 | Improved motor function in some trials |
| Diffuse intrinsic pontine glioma (DIPG) | Chemotherapy | Phase 1 | Direct tumor delivery |
| Brain tumors | Various | Phase 1-2 | Multiple trials |
| Rare CNS disorders | Various | Preclinical | Investigational |
Gene Therapy Delivery via CED
Comparison: CED vs. ICV/ICM Delivery
| Factor | CED | ICV/ICM |
|---|---|---|
| Distribution | Bulk flow (cm scale) | Diffusion (mm scale) |
| Coverage | Can cover entire hemisphere | Limited to ventricle-adjacent |
| Invasiveness | Requires surgery | Requires surgery |
| Precision | Targeted to specific regions | Diffusion-dependent |
| Reversibility | N/A | N/A |
| Re-dosing | Possible with new catheters | Possible |
| Company/Institution | Focus | Status |
|---|---|---|
| BrainCyte (formerly SureGene) | CNS gene therapy via CED | Preclinical |
| Various academic | Parkinson's (AAV-AADC) | Phase 1-2 |
| Various academic | Brain tumor delivery | Phase 1-2 |
| Syner-G | CED catheter technology | Device development |
Dravet syndrome (also known as Severe Myoclonic Epilepsy of Infancy, SMEI) is a catastrophic developmental and epileptic encephalopathy caused by heterozygous loss-of-function mutations in SCN1A. The disease affects approximately 1 in 15,000-20,000 births, making it one of the most common genetic epilepsies. Core features include:
| Approach | Example | Efficacy | Limitations |
|---|---|---|---|
| Sodium channel blockers | Fenfluramine (FDA-approved 2020) | 50-70% responder | Refractory patients still exist |
| CBD | Epidiolex (FDA-approved 2018) | Adjunct therapy | Drug interactions |
| VNS therapy | Pacemaker-like device | ~50% seizure reduction | Surgical risks |
| ASO | STK-001 (Stoke) | Phase 1/2 | Intrathecal delivery |
| Gene therapy | AAV-SCN1A (Encoded) | Preclinical | Packaging, delivery |
1. Stoke Therapeutics — STK-001 (ASO)
2. Encoded Therapeutics — ETX101 (AAV gene activation)
3. AAV-SCN1A Full Gene Delivery
| Company | Modality | Stage | Key Differentiator |
|---|---|---|---|
| Stoke Therapeutics | ASO | Phase 2 (BEACON) | Phase 2 data Q2-Q3 2026; FDA BTD; BLA prep |
| Encoded Therapeutics | AAV-CRISPRa | Phase 1 (LAYLA) | First patient dosed Q1 2026; single-dose potential |
| Roche/Neurocrine | AAV | IND-enabling | Large pharma resources; 2027 IND expected |
| UC Berkeley (Bhatt) | AAV | Preclinical | Academic, optimized serotype |
KCNQ2 encephalopathy is caused by pathogenic variants in the KCNQ2 gene, which encodes the Kv7.2 potassium channel subunit. Unlike SCN1A (loss-of-function), KCNQ2 variants can be either loss-of-function (most common) or gain-of-function. Features include:
| Entity | Status | Approach |
|---|---|---|
| Academic (CHOP) | Preclinical | AAV-KCNQ2 |
| Academic (UCSF) | Research | AAV-shRNA for GoF variants |
CDKL5 deficiency disorder (CDD) is caused by mutations in the CDKL5 gene (cyclin-dependent kinase-like 5), located on the X chromosome. Affects primarily females (male lethal in most cases). Features:
Angelman syndrome is caused by loss of maternal UBE3A expression in the brain. The maternal allele is normally active while the paternal allele is silenced (imprinting). Key features:
1. GeneTx/Ultragenyx — GTX-102 (ASO)
2. AAV-UBE3A Gene Replacement
3. UBE3A-ATS ASO (GeneTx)
| Company | Modality | Stage | Status |
|---|---|---|---|
| GeneTx/Ultragenyx | ASO (GTX-102) | Phase 2 | BLA submission expected Q3-Q4 2026 |
| Roche | ASO | Discovery | Partnership with GeneTx |
| Various academic | AAV | Preclinical | Research stage |
STXBP1 encephalopathy (also known as STXBP1-E) is caused by pathogenic variants in the STXBP1 gene, which encodes Munc18-1, a critical protein for synaptic vesicle release. This is one of the most common causes of early infantile epileptic encephalopathy (EIEE). Key features include:
| Entity | Status | Approach |
|---|---|---|
| Academia (multiple groups) | Research | AAV-STXBP1 replacement |
| Roche | Discovery | STXBP1-targeted approach (broader CNS portfolio) |
| Various biotech | Preclinical | Gene therapy for STXBP1-E |
SLC6A1 (also known as GAT1) encodes the GABA transporter 1, responsible for GABA reuptake in the brain. Pathogenic variants cause a spectrum of neurodevelopmental disorders:
| Entity | Status | Approach |
|---|---|---|
| Takeda/SBI | Preclinical | AAV-SLC6A1 gene therapy |
| Various academic | Research | Gene replacement approaches |
GABRB3 (GABA-A receptor beta3 subunit) is located in the 15q12 region, within the Angelman syndrome critical region. Pathogenic variants in GABRB3 cause a spectrum of neurodevelopmental disorders including:
| Entity | Status | Approach |
|---|---|---|
| Academia (multiple groups) | Research | AAV-GABRB3 replacement |
| Various biotech | Discovery | Gene therapy for GABRB3-E |
PCDH19 (Protocadherin 19) is an X-linked gene that causes epilepsy and intellectual disability in females. The disorder is also known as EFMR (Epilepsy and Intellectual Disability in Females). Key features include:
| Entity | Status | Approach |
|---|---|---|
| Academia (multiple groups) | Research | AAV-PCDH19 replacement |
| Various biotech | Discovery | Gene therapy for PCDH19 |
Note: Dedicated preclinical program page has been created:
| Company | Event | Amount | Year | Strategic Rationale |
|---|---|---|---|---|
| Encoded Therapeutics | Series C | $135M | 2023 | SCN1A gene activation (ETX101) |
| Stoke Therapeutics | IPO (NASDAQ) | $125M | 2020 | SCN1A ASO platform |
| Stoke Therapeutics | Follow-on | $90M | 2023 | STK-001/002 expansion |
| Stoke Therapeutics | Follow-on | $65M | 2025 | Phase 2 BLA prep, manufacturing investment |
| Ultragenyx (GeneTx) | Acquisition | $400M+ | 2019 | Angelman ASO (GTX-102) |
| Roche/Neurocrine | Partnership | $150M+ upfront | 2021 | SCN1A program |
| Encoded Therapeutics | Series B | $70M | 2021 | Platform development |
| Encoded Therapeutics | Series A | $30M | 2019 | Founding round |
| Encoded Therapeutics | Series D | $80M | 2025 | ETX101 Phase 1 initiation, manufacturing scale-up |
| Company | Market Cap | Key Program | Stage |
|---|---|---|---|
| Stoke Therapeutics (STOK) | ~$800M-1B | STK-001 (Dravet) | Phase 2, BLA prep |
| Ultragenyx (UGX) | ~$2-3B | GTX-102 (Angelman) | Phase 2, BLA submission |
| Ionis Pharmaceuticals | ~$5B | Multiple ASOs | Various |
| Factor | Dravet (SCN1A) | Angelman (UBE3A) | KCNQ2 | CDKL5 | STXBP1 | SLC6A1 | GABRB3 | PCDH19 |
|---|---|---|---|---|---|---|---|---|
| Target validity | High — causal gene | High — causal, imprinting mechanism | Moderate — variable phenotype | High — causal | High — causal | High — causal | High — causal | High — causal |
| Technical risk | Moderate — packaging | Low — ASO well-validated | Moderate | Low — fits in AAV | Low — fits in AAV | Low — fits in AAV | Low — fits in AAV | Low — fits in AAV |
| Regulatory path | Clear (FDA orphan) | Clear | Clear | Clear | Clear | Clear | Clear | Clear |
| Commercial opportunity | $1B+ (rare disease, high unmet need) | $500M-1B | $300-500M | $300-500M | $200-400M | $200-400M | $200-400M | $300-500M |
| Competition | Moderate | Low | Low | Low | Low | Low | Low | Low |
The FDA's accelerated approval pathway is particularly relevant for NDE gene therapies given the high unmet need and limited treatment options. Key considerations include:
1. Orphan Drug Designation (ODD)
2. Rare Pediatric Disease Priority Review Voucher (PRV)
3. Accelerated Approval Based on Surrogate Endpoints
4. Breakthrough Therapy Designation
| Challenge | Regulatory Strategy |
|---|---|
| Long-term follow-up requirements | Post-marketing commitments, disease registries |
| Pediatric population | Clear juvenile toxicology packages, age-appropriate endpoints |
| Valid biomarker development | Qualification through FDA's biomarker qualification program |
| Single-arm trial design | Natural history as comparator, historical controls |
| Combination products | Center for Drug Evaluation and Research (CDER) + Center for Biologics Evaluation and Research (CBER) coordination |
| Region | Pathway | Key Considerations |
|---|---|---|
| EU (EMA) | PRIME designation, Adaptive Pathways | Early engagement, conditional approval |
| UK (MHRA) | ILAP designation | Innovative licensing and access pathway |
| Japan (PMDA) | Sakigake designation | Priority review, early approval |
| Australia (TGA) | Priority determination | Streamlined pathways for rare disease |
1. Disease Registries
2. Patient-Reported Outcomes (PROs)
3. Digital Health Technologies
| Component | Implementation |
|---|---|
| Long-term follow-up | 15-year follow-up per FDA guidance for AAV |
| Pharmacovigilance | Active surveillance via registries |
| Real-time safety | Integration with FDA Sentinel System |
| ** immunogenicity monitoring** | Anti-AAV antibody titers, T-cell responses |
Note: Dedicated clinical trial pages have been created for key programs. See:
- STK-001 (Stoke Therapeutics) — Dravet Phase 1/2 Trial
- ETX101 (Encoded Therapeutics) — Dravet Gene Activation Therapy
- GTX-102 (GeneTx/Ultragenyx) — Angelman Phase 1/2 Trial
- Vigonvita CDKL5 Deficiency — Preclinical Program
- STXBP1 Encephalopathy — Preclinical Program
- KCNQ2 Encephalopathy — Gene Therapy Preclinical Programs
- PCDH19 Epilepsy — Preclinical Program
- Roche/Neurocrine SCN1A AAV Gene Therapy — Dravet Syndrome
Trial Design:
Endpoints:
Key Results (2024-2025):
50% seizure reduction in >50% of responders at highest dose cohort (30mg, 50mg)
Approach: AAV9-delivered CRISPR-activator (CRISPRa) targeting SCN1A promoter
Delivery: Intra-cisterna magna (ICM)
Status: Phase 1 clinical trial initiated Q1 2026 (first patient dosed)
Trial Design Considerations:
Trial Design:
Endpoints:
Results to Date (2025):
Current Status: No active clinical trials for gene therapy as of 2025
Academic groups at CHOP and UC Davis in preclinical development
Natural history studies ongoing to establish endpoints
See dedicated page: KCNQ2 Encephalopathy — Gene Therapy Preclinical Programs
| Research Group | Institution | Approach | Status | Key Publications |
|---|---|---|---|---|
| Dr. Eric Marsh | CHOP | AAV-KCNQ2 | Preclinical | Ongoing research |
| Dr. Scott J. Golde | UC Davis | AAV delivery | Precharacterization | — |
Challenges for KCNQ2 gene therapy:
Current Status: No active clinical trials yet; Vigonvita program in IND-enabling studies
| Research Group | Institution | Approach | Status | Key Publications |
|---|---|---|---|---|
| Vigonvita Therapeutics | Industry | AAV-CDKL5 | Preclinical | IND-enabling studies |
Challenges for CDKL5 gene therapy:
Beyond the clinical-stage programs, multiple academic and industry groups are advancing NDE gene therapies through preclinical development. This section tracks these programs and their development timelines.
| Program | Institution/Company | Vector | Approach | Development Stage |
|---|---|---|---|---|
| AAV-SCN1A | Roche/Neurocrine | AAV9 | Gene replacement | Discovery |
| Mini-SCN1A | UC Berkeley (Bhatt) | AAV | Truncated construct | Preclinical |
| CRISPRa-SCN1A | Encoded Therapeutics | AAV | Activation | IND-enabling |
| Program | Institution/Company | Vector | Approach | Development Stage |
|---|---|---|---|---|
| GTX-102 | GeneTx/Ultragenyx | ASO | Approved | Phase 1/2 |
| AAV-UBE3A | Various academic | AAV | Gene replacement | Research |
| Program | Institution/Company | Vector | Approach | Development Stage |
|---|---|---|---|---|
| AAV-KCNQ2 | CHOP | AAV9 | Gene replacement | Preclinical |
| AAV-KCNQ2 | UC Davis | AAV | Gene replacement | Research |
| Program | Institution/Company | Vector | Approach | Development Stage |
|---|---|---|---|---|
| AAV-CDKL5 | Vigonvita | AAV9 | Gene replacement | IND-enabling |
| Program | Institution/Company | Vector | Approach | Development Stage |
|---|---|---|---|---|
| AAV-STXBP1 | Academic | AAV | Gene replacement | Research |
| Program | Institution/Company | Vector | Approach | Development Stage |
|---|---|---|---|---|
| AAV-GABRB3 | Academic | AAV | Gene replacement | Research |
| Program | Institution/Company | Vector | Approach | Development Stage |
|---|---|---|---|---|
| AAV-PCDH19 | Academic | AAV | Gene replacement | Research |
| Platform | Advantages | Limitations | Scalability |
|---|---|---|---|
| Triple transfection (HEK293) | Flexible serotype, high titer | Complex, expensive | Good |
| Baculovirus/Sf9 | High yield, large scale | Limited serotype flexibility | Excellent |
| Stable producer cell line | Consistent, lower cost | Long development time | Excellent |
| Suspension culture | Scalable, lower cost | Technical complexity | Excellent |
| Cost Component | Typical Range | Notes |
|---|---|---|
| GMP manufacturing | $500K-2M per batch | Scale dependent |
| Fill-finish | $100K-300K per batch | Sterile fill |
| Quality control | $200K-500K per batch | Extensive testing |
| Total per dose | $1M-5M | Including release testing |
| Organization | Focus | Role |
|---|---|---|
| Dravet Syndrome Foundation | Dravet | Research funding, family support, clinical trial advocacy |
| Angelman Syndrome Foundation | Angelman | Research funding, family conferences, advocacy |
| Cute Syndrome Foundation | CDKL5 | Research funding, family support |
| Ring14 USA | Ring14 chromosome | Family support, research |
| SLC6A1 Connect | SLC6A1 | Patient registry, research |
| STXBP1 Foundation | STXBP1 | Research funding, family support |
| PCDH19 Alliance | PCDH19 | Patient registry, research |
| Disease | Study | Sponsor | Status |
|---|---|---|---|
| Dravet | RDCRN DM1B | Taysha/UCB | Ongoing |
| Angelman | N=400 registry | Angelman Foundation | Recruiting |
| CDKL5 | RDCRN DM1B | Cute Syndrome Foundation | Ongoing |
| KCNQ2 | RDCRN | KCNQ2 Cure Foundation | Recruiting |
| STXBP1 | STXBP1 Registry | STXBP1 Foundation | Recruiting |
| PCDH19 | PCDH19 Registry | PCDH19 Alliance | Ongoing |
| SLC6A1 | SLC6A1 Registry | SLC6A1 Connect | Recruiting |
| Ring14 | Ring14 Registry | Ring14 USA | Ongoing |
Intranasal delivery represents a non-invasive approach to bypass the blood-brain barrier by leveraging the olfactory pathway directly to the CNS. This method has gained attention as an alternative to surgical delivery routes (ICV/ICM) and may reduce systemic exposure and surgical risks.
| Advantage | Description |
|---|---|
| Non-invasive | No surgery, reduces procedural risks in pediatric patients |
| Repeatable | Can re-dose if needed without surgical concerns |
| Lower systemic exposure | Reduced off-target effects and immunogenicity |
| Early intervention | Potential for treatment in infancy without major surgery |
| Cost-effective | Simpler administration than ICV/ICM |
| Parameter | Notes |
|---|---|
| Particle size | Optimal: 10-100nm; larger particles trapped in nasal cavity |
| Surface charge | Neutral to slightly positive enhances absorption |
| Mucoadhesive agents | Chitosan, poloxamer for enhanced retention |
| Formulation | Must protect vector from nasal enzymes and pH |
| Factor | Impact |
|---|---|
| Vector type | AAV less efficient than smaller particles |
| Age | Young mice show higher transduction than adults |
| Volume | Smaller volumes (20-50μL) better than larger |
| Timing | Fasting state improves absorption |
Dravet Syndrome (SCN1A)
Angelman Syndrome (UBE3A)
KCNQ2, CDKL5, STXBP1
| Company/Institution | Focus | Status |
|---|---|---|
| Various academic | AAV nasal delivery for CNS | Research |
| Kurve Therapeutics | Intranasal platform | Preclinical |
| neuronasal | Non-invasive CNS delivery | Research |
| Factor | Intranasal | ICV/ICM | IV + FUS | IV (systemic) |
|---|---|---|---|---|
| Invasiveness | None | Surgical | Non-invasive | Non-invasive |
| BBB bypass | Yes | Yes | Temporary | No |
| Coverage | Limited (olfactory) | Moderate | Broad | Limited |
| Repeatable | Yes | Limited | Yes | Limited |
| Pediatric suitable | Yes | Yes | Yes | Yes |
| Technical complexity | Low | High | High | Low |
Biomarkers serve multiple critical functions in NDE gene therapy development:
| Biomarker | Disease | Application |
|---|---|---|
| SCN1A variant type | Dravet | Allele-specific ASO design |
| UBE3A mutation type | Angelman | Approach selection (ASO vs. gene replacement) |
| KCNQ2 variant classification | KCNQ2-E | Loss-of-function vs. gain-of-function |
| Biomarker | Detection Method | Disease | Status |
|---|---|---|---|
| Nav1.1 protein expression | IHC/Western blot | Dravet | Research |
| SCN1A mRNA levels | qPCR | Dravet | Clinical (CSF) |
| UBE3A expression | IHC | Angelman | Clinical (skin biopsy) |
| Kv7.2 channel function | Electrophysiology | KCNQ2 | Research |
| Biomarker | Target | Disease | Notes |
|---|---|---|---|
| SCN1A expression | Nav1.1 protein | Dravet | STK-001 uses as endpoint |
| Neurofilament light (NfL) | Axonal injury | Multiple | General neurodegeneration |
| Tau/phospho-tau | Tau pathology | Multiple | Not NDE-specific |
| YKL-40 | Neuroinflammation | Multiple | Astrocyte activation |
| Biomarker | Method | Disease | Utility |
|---|---|---|---|
| Seizure frequency | Diary + EEG | All NDE | Primary endpoint |
| EEG normalization | Quantitative EEG | All NDE | Secondary endpoint |
| Background slowing | EEG | Angelman | Clinical improvement |
| Interictal spikes | EEG | Dravet | Treatment response |
| Biomarker | Method | Disease | Status |
|---|---|---|---|
| Brain volume | MRI | All NDE | Developmental tracking |
| White matter integrity | DTI | Multiple | Research |
| Metabolism | FDG-PET | All NDE | Research |
| Neuroinflammation | TSPO-PET | Research | Early |
| Strategy | Biomarker | Application |
|---|---|---|
| Dose-finding | Expression biomarker | Optimize dosing based on target engagement |
| Patient stratification | Genetic + expression | Select patients most likely to respond |
| Go/No-go decisions | Early expression changes | Guide development timeline |
| Accelerated approval | Surrogate endpoint | Enable earlier approval based on biomarker |
| Company | Program | Biomarker Focus |
|---|---|---|
| Stoke Therapeutics | STK-001 | Nav1.1 expression in CSF |
| GeneTx/Ultragenyx | GTX-102 | UBE3A reactivation (skin biopsy) |
| Encoded Therapeutics | ETX101 | SCN1A mRNA expression |
| Various academic | Multiple | NfL, electrophysiology |
Clinical endpoints in NDE gene therapy trials must balance regulatory requirements, clinical meaningfulness, and practical measurement in pediatric populations. Unlike adult trials, endpoints must account for developmental trajectories, caregiver-reported outcomes, and age-appropriate assessments.
| Endpoint | Definition | Advantages | Limitations |
|---|---|---|---|
| Seizure frequency | % change from baseline | Objective, widely accepted | Variability in reporting |
| Seizure freedom | Zero seizures in period | Clinically meaningful | Rare in NDE |
| Response rate | ≥50% reduction | Standard definition | May miss subtle benefits |
| Status epilepticus frequency | Number of SE events | High clinical impact | Rare events |
Key Consideration: Seizure diaries are caregiver-reported and may have gaps. Continuous EEG provides objective verification but is resource-intensive.
| Endpoint | Instrument | Age Range | Notes |
|---|---|---|---|
| Cognitive function | Bayley-3, BSID-III | 1-42 months | Gold standard for infants/toddlers |
| Adaptive behavior | Vineland-3 | All ages | Caregiver-report |
| Motor function | Peabody, GMFM | All ages | Gross motor assessment |
| Communication | Mullen, ADOS | All ages | Language development |
Key Consideration: NDE patients often have baseline deficits. Endpoint must be change from baseline, not absolute score.
| Endpoint | Description | Age | Notes |
|---|---|---|---|
| PedsQL | Quality of life | 2-18 | Parent + child report |
| EQ-5D-Y | Utility measure | 4-18 | Health economics |
| Caregiver burden | Zarit scale | N/A | Family impact |
| CGI-C/I | Global impression | All | Clinician-rated |
| Endpoint | Method | Utility |
|---|---|---|
| EEG normalization | Quantitative EEG | Objective measure |
| Background improvement | EEG | Clinical correlation |
| Interictal epileptiform | EEG | Treatment effect |
| Seizure burden on EEG | Long-term monitoring | Objective |
| Priority | Endpoint | Rationale |
|---|---|---|
| Primary | Seizure frequency reduction | Most clinically meaningful |
| Secondary | CGI-C, Vineland-3 | Functional improvement |
| Exploratory | EEG normalization, NfL | Biomarker correlation |
| Priority | Endpoint | Rationale |
|---|---|---|
| Primary | Bayley-3 cognitive score | Key deficit area |
| Secondary | EEG normalization | Objective measure |
| Exploratory | ABC-C, UBE3A expression | Behavioral, biomarker |
| Priority | Endpoint | Rationale |
|---|---|---|
| Primary | Seizure frequency | Primary disease manifestation |
| Secondary | Developmental assessment | Key comorbidity |
| Exploratory | EEG background | Treatment effect |
| Drug | Disease | Endpoint Strategy |
|---|---|---|
| Epidiolex (CBD) | Dravet, LGS | Seizure frequency |
| Fenfluramine | Dravet | Seizure frequency, CGI-C |
| Spinraza (ASO) | SMA | Motor function, survival |
| Zolgensma (AAV) | SMA | Motor function, survival |
The high upfront cost of gene therapies ($1-3M for one-time treatments) requires comprehensive value assessment frameworks that consider:
Clinical Value Components:
| Component | Measurement | Impact on Value |
|---|---|---|
| Seizure reduction | % responder rate, seizure freedom | High |
| Developmental preservation | IQ/DQ maintenance, milestone achievement | Very High |
| Mortality reduction | SUDEP prevention | Very High |
| Caregiver burden | Time savings, QoL | High |
| Long-term disease modification | Reduced progression | Very High |
Economic Value Components:
Historical Precedents:
| Therapy | Indication | List Price | ICER Threshold |
|---|---|---|---|
| Zolgensma | SMA | $2.1M | Cost-effective at $500K/QALY |
| Luxturna | LCA | $850K | Cost-effective at $500K/QALY |
| HemgenA | Hemophilia | $3.5M (over time) | Debated |
NDE-Specific Pricing Considerations:
Evidence Requirements:
Access Framework:
United States:
European Union:
Asia-Pacific:
Most gene therapy developers offer:
Gene therapies for neurodevelopmental epilepsies require comprehensive long-term safety monitoring given their potential for decades of expression in pediatric patients. Unlike small molecule drugs that are cleared within hours to days, AAV-mediated gene therapy can result in persistent transgene expression for years to decades, necessitating unique safety surveillance approaches.
| Risk | Description | Monitoring Approach |
|---|---|---|
| Genomic integration | AAV can integrate into host genome, potentially disrupting genes | Long-term integration site analysis, WGS in preclinical models |
| Off-target tissue expression | Expression in non-target organs (liver, heart) | Tissue biodistribution studies, PK/PD monitoring |
| Immunogenicity | Immune response to vector capsid or transgene | Anti-capsid antibodies, T-cell responses, cytokine panels |
| Insertional mutagenesis | Theoretical cancer risk from integration | Regular surveillance imaging, tumor markers |
| Germline transmission | Vector DNA in reproductive tissues | Reproductive toxicology studies |
| Gene | Specific Concerns | Mitigation Strategies |
|---|---|---|
| SCN1A | Altered sodium channel function, potential for gain-of-function | Careful promoter selection, cell-type specificity |
| KCNQ2 | Channel overexpression, cardiac effects | Dose optimization, ECG monitoring |
| CDKL5 | Cell cycle effects, potential for tumorigenicity | Long-term oncogenic monitoring |
| UBE3A | Altered ubiquitin pathway | Preclinical safety assessment |
| STXBP1 | Synaptic function alterations | Behavioral monitoring |
| Route | Specific Risks | Monitoring |
|---|---|---|
| Intrathecal | CSF leak, meningitis, spinal cord injury | Neurological exams, CSF analysis |
| ICV/ICM | Intracranial hemorrhage, CNS infection | Neuroimaging, ICP monitoring |
| IV + FUS | BBB disruption-associated edema | MRI with contrast, clinical monitoring |
| Systemic | Liver toxicity, complement activation | LFTs, complement panels |
1. Long-Term Registry Studies
2. Safety Monitoring Milestones
| Timepoint | Key Assessments |
|---|---|
| Day 0-7 (acute) | Immediate adverse events, CRS monitoring |
| Week 1-4 | Laboratory parameters, liver function |
| Month 1-3 | Neuroimaging, antibody titers |
| Month 6-12 | Developmental assessments, seizure frequency |
| Year 1-5 | Annual comprehensive evaluation |
| Year 5-15 | Long-term developmental, oncogenic monitoring |
| Year 15+ | Continued surveillance, reproductive health |
3. Required Pharmacovigilance Activities
| Frequency | Events | Management |
|---|---|---|
| Very common (>10%) | Headache, nausea, pyrexia, CSF pleocytosis | Supportive care, pre-medication |
| Common (1-10%) | Elevated liver enzymes, mild CRS, injection site reactions | Monitor, dose modification |
| Uncommon (0.1-1%) | Severe CRS, hepatic dysfunction, neurological symptoms | Hospitalization, immunomodulation |
| Rare (<0.1%) | Insertional mutagenesis, severe neurotoxicity | Specialized intervention |
Cytokine Release Syndrome (CRS) Management:
Liver Enzyme Elevation Management:
| Regulatory Body | Key Requirements |
|---|---|
| FDA | 15-year follow-up, annual BLA updates, REMS program |
| EMA | PAES (Post-Authorization Efficacy Studies), risk management plan |
| PMDA | Comparable to FDA/EMA, additional post-marketing surveillance |
| Health Canada | Similar requirements, mandatory registry participation |
| Domain | Measures | Assessment Frequency |
|---|---|---|
| Seizure control | Seizure frequency, responder rate, seizure freedom | Monthly diary, annual review |
| Neurodevelopment | IQ/DQ, adaptive behavior, language | Baseline, 1, 3, 5, 10, 15 years |
| Quality of life | PedsQL, caregiver burden | Baseline, annually |
| Safety | AEs, SAEs, laboratory parameters | Continuous |
| Mortality | All-cause mortality, SUDEP | Continuous |
| Component | Estimated Annual Cost per Patient |
|---|---|
| Registry management | $5,000-10,000 |
| Annual assessments | $3,000-5,000 |
| Laboratory monitoring | $1,000-2,000 |
| Data analysis/reporting | $2,000-3,000 |
| Total | $11,000-20,000/year |
Successful long-term monitoring programs:
Best practice elements:
As of March 2026, several programs have reached key inflection points. This section tracks the competitive landscape with updated timelines reflecting current development status.
| Company | Program | 2024 (actual) | 2025 (actual) | 2026 (current) | 2027 | 2028 |
|---|---|---|---|---|---|---|
| Stoke Therapeutics | STK-001 | Phase 1/2 data readout | Phase 2 enrollment | Phase 2 data Q2-Q3, BLA prep | BLA filing | Potential approval |
| Encoded Therapeutics | ETX101 | IND-enabling | IND filed (mid-2025) | Phase 1 initiation Q1-Q2 | Phase 1/2 | Phase 2 |
| GeneTx/Ultragenyx | GTX-102 | Phase 1/2 | Phase 2 data readout | BLA submission | Potential approval | — |
| Roche/Neurocrine | SCN1A | Discovery | Preclinical | IND-enabling | Phase 1 | Phase 1/2 |
| Vigonvita | CDKL5 | Preclinical | IND-enabling | IND filed | Phase 1 initiation | Phase 1/2 |
Pediatric patients represent the primary target population for NDE gene therapies, making age-appropriate dosing considerations critical for success. Unlike adult populations, pediatric CNS drug development requires careful consideration of developmental changes in physiology, brain volume, and clearance mechanisms that affect vector biodistribution and expression.
| Factor | Consideration | Impact |
|---|---|---|
| Brain volume | ~35% of adult at birth | Higher dose per kg may be needed for CNS coverage |
| BBB maturity | More permeable in neonates | Potential for enhanced delivery but also higher systemic exposure |
| CSF volume | ~50% adult volume | Reduced dilution of intrathecal/ICV delivery |
| Immune status | Naive to most pathogens | Lower pre-existing antibody concerns but developing immunity |
| Age Group | Typical Dose Range (AAV9) | Notes |
|---|---|---|
| <6 months | 1-2 × 10¹⁴ GC/kg | Higher per-weight for brain coverage |
| 6-12 months | 1-1.5 × 10¹⁴ GC/kg | Adjusted for BBB maturation |
| 1-5 years | 0.8-1.2 × 10¹⁴ GC/kg | Standard pediatric range |
| >5 years | Similar to adult | 1 × 10¹⁴ GC/kg typical |
| Route | Dose Adjustment Factor | Rationale |
|---|---|---|
| ICV/ICM | 0.5-0.7× systemic | Direct CNS delivery, bypass BBB |
| Intrathecal | 0.7-0.8× systemic | CSF distribution |
| IV | Standard weight-based | Requires crossing BBB |
| Program | Target | Age | Dose | Key Findings |
|---|---|---|---|---|
| Zolgensma (onasemnogene) | SMN1 | <2 years | 2×10¹⁴ GC/kg IV | Efficacy at this dose, monitoring for long-term |
| Luxturna (voretigene) | RPE65 | >4 years | 1.5×10¹¹ GC/eye | Safe in pediatric population |
| Strimvelis (ADA-SCID) | ADA | >4 years | Autologous BMT | Long-term expression |
Digital health technologies are transforming NDE clinical trials by enabling continuous monitoring, improving endpoint capture, and reducing caregiver burden. For gene therapy trials requiring long-term follow-up, digital endpoints offer objective, consistent measurements that complement traditional clinical assessments.
| Device | Company | Detection Method | FDA Status | NDE Applicability |
|---|---|---|---|---|
| Embrace2 | Empatica | Accelerometer + EDA | Cleared | seizure monitoring |
| EpiMonitor | Cerebrel | EEG + AI | Investigational | seizure classification |
| SAMi | Neuroview | EEG | Cleared | nighttime seizures |
| UNEEG | UNEEG Medical | Subcutaneous EEG | CE marked | continuous monitoring |
| Domain | Biomarker | Technology | Validation Status |
|---|---|---|---|
| Seizure | Event frequency, duration | Wearable AI | Good |
| Motor | Gait analysis, ataxia | Accelerometry | Moderate |
| Development | Movement quality | Video analysis | Early |
| Sleep | Sleep architecture | Wearable | Good |
| Cognition | Attention, response time | Tablet tasks | Early |
| Timepoint | Digital Assessments | Purpose |
|---|---|---|
| Month 1-3 | Weekly seizure diary review | Early signal detection |
| Month 3-6 | Continuous wearable monitoring | Dose-response |
| Month 6-12 | Quarterly comprehensive | Sustained benefit |
| Year 1-5 | Annual + event-driven | Long-term tracking |
| Company | Program | Digital Component |
|---|---|---|
| Stoke Therapeutics | STK-001 | Continuous EEG monitoring, seizure diaries |
| Encoded Therapeutics | ETX101 | Digital motor assessments |
| Roche/Neurocrine | SCN1A | Wearable integration in trials |
| Various academic | Natural history studies | Remote monitoring platforms |
As NDE gene therapies advance toward approval, understanding global access pathways is critical for patients, families, and developers. Compassionate use, early access programs, and regional approval strategies vary significantly across jurisdictions.
| Pathway | Timeline | Key Requirements |
|---|---|---|
| Standard BLA | 10-12 months | Full efficacy/safety package |
| Accelerated Approval | 6-8 months | Surrogate endpoint, confirmatory trial |
| Priority Review | 6 months | Significant unmet need |
| Breakthrough Therapy | Rolling review | Substantial improvement |
| Pathway | Timeline | Key Requirements |
|---|---|---|
| Standard MAA | 12-18 months | Full package |
| Conditional Approval | 6-9 months | Serious disease, benefit-risk positive |
| PRIME | Accelerated | Promising therapy addressing unmet need |
| Region | Pricing Model | Reimbursement Timeline |
|---|---|---|
| US | Value-based, indications-based | 6-12 months post-approval |
| Germany | Reference pricing, AMNOG | 6-12 months |
| UK | NICE evaluation | 12-18 months |
| Japan | National health insurance | 9-12 months |
Translating gene therapy from preclinical models to human clinical outcomes remains one of the biggest challenges in NDE development. Species differences in CNS anatomy, immune response, and developmental timing create significant barriers to predicting efficacy.
| Model Type | Applications | Limitations |
|---|---|---|
| Knockout (KO) | Gene function, seizure phenotyping | Lacks human regulatory elements |
| Knock-in (KI) | Disease-causing variants | May not fully replicate human phenotype |
| Humanized | Human gene expression | Complex, expensive |
Key Considerations for Mouse Models:
| Application | Utility |
|---|---|
| Disease modeling | Patient-derived neurons show disease phenotypes |
| Drug screening | Test therapeutic candidates in human cells |
| Mechanism studies | Understand pathophysiology |
| Toxicity screening | Assess off-target effects |
Limitations:
| Species | Advantages | Disadvantages |
|---|---|---|
| Pig | Brain size similar to human, gyrencephalic | Cost, housing |
| NHP | Closest to human CNS, immune relevance | Ethical concerns, cost |
Value for NDE Programs:
FDA and EMA require:
Understanding the natural history of neurodevelopmental epilepsies is critical for clinical trial design, endpoint selection, and regulatory approval. Natural history studies establish baseline disease progression, identify meaningful clinical endpoints, and provide comparator data for treatment effects.
NDEs are characterized by early-onset seizures, developmental regression, and heterogeneous phenotypes. Natural history studies help characterize:
| Study | Sponsor | Cohort | Key Findings |
|---|---|---|---|
| Dravet Syndrome Natural History | RDCRN DM1B | N=500+ | Seizure onset median 5 months, SCN1A variant hot spots identified |
| Genesis Dravet | Taysha/UCB | N=200 | Developmental plateau by age 3-5, SUDEP risk highest in adolescence |
| FRaISE | French consortium | N=150 | Temperature-triggered seizures decline after childhood |
Key endpoints being validated:
| Study | Sponsor | Cohort | Key Findings |
|---|---|---|---|
| Angelman Registry | Angelman Foundation | N=400+ | 80% develop seizures, communication limited to non-verbal |
| AS Natural History | ASF/NIH | N=300 | Sleep disturbance, ataxia, happy demeanor stable across lifespan |
Key endpoints being validated:
| Study | Sponsor | Cohort | Key Findings |
|---|---|---|---|
| CDKL5 Natural History | RDCRN DM1B | N=200+ | Early infantile onset (3-12 months), refractory seizures |
| Loulou Foundation | Industry consortium | N=150 | Male lethality ~70%, gross motor impairment severe |
Key endpoints being validated:
| Study | Sponsor | Cohort | Key Findings |
|---|---|---|---|
| KCNQ2 Natural History | RDCRN | N=100+ | Burst-suppression EEG in neonatal period, variable outcome |
| KCNQ2 Registry | Academic consortium | N=80 | ~50% severe ID, 50% moderate ID |
Key endpoints being validated:
Gene therapy for NDE is unlikely to replace existing anti-seizure medications (ASMs) entirely. Most patients will continue using adjunctive therapies, making understanding of drug-drug interactions (DDIs) and combination strategies critical for optimal clinical outcomes.
| Drug | Indication | Mechanism | Combination Potential with Gene Therapy |
|---|---|---|---|
| Fenfluramine | Dravet | 5-HT2C agonist + sigma-1 agonist | Likely continued post-gene therapy |
| CBD (Epidiolex) | Dravet, LGS | Multiple (TRPV1, GPR55, etc.) | Likely continued as adjunct |
| Clobazam | Multiple | GABA-A modulator | May be reduced post-response |
| Valproic acid | Multiple | HDAC inhibitor, multiple | May be reduced post-response |
| Stiripentol | Dravet | GABAA positive allosteric | Likely continued short-term |
| Levetiracetam | Multiple | SV2A modulator | Continue as needed |
| Perampanel | Multiple | AMPA antagonist | May be reduced post-response |
| Gene Therapy Type | ASM Concern | Mechanism | Management |
|---|---|---|---|
| AAV-ASMs | None known | Viral vector, different mechanism | No DDI expected |
| ASO-ASMs | Potential synergism | Different targets may be additive | Monitor for enhanced effect |
| CRISPRa-ASMs | None known | Transcriptional upregulation | No DDI expected |
| Age Group | ASM Approach | Notes |
|---|---|---|
| Neonates (<1mo) | Limited ASM options | Phenobarbital first-line |
| Infants (1-12mo) | Fenfluramine + CBD | Limited pediatric data |
| toddlers (1-3yr) | Standard ASMs | Weight-based dosing |
| Children (3-12yr) | Full ASM range | Most data available |
| Adolescents | Adult regimens | Full range available |